Arrowstreet Capital
NDRM

Arrowstreet Capital’s NeuroDerm Ltd. Ordinary Shares NDRM Stock Holding History

Arrowstreet Capital’s Portfolio NDRM Stock Details NDRM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-10,600
Closed -$181K – 1761
2015
Q4 		$181K Buy
+10,600
New +$206K ﹤0.01% 1319

Other funds holding NDRM

SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return
GC
GMT Capital Atlanta, Georgia $2.19B AUM 72.3% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
FCMI
Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
SAM
Senzar Asset Management New York $34.7M AUM 0.56% 1-Year Est. Return

Arrowstreet Capital's NDRM Position: Q1 2016 in Review

Arrowstreet Capital sold out of NeuroDerm Ltd. Ordinary Shares (NDRM) in Q1 2016, closing a stake of 10,600 shares — an estimated $181K sold.

Arrowstreet Capital first reported a position in NDRM in Q4 2015 and held it in 1 quarter. The position peaked at $181K in Q4 2015. 50 funds tracked by Wall St. Rank hold NDRM as of Q1 2016.

  • Arrowstreet Capital reported no remaining NeuroDerm Ltd. Ordinary Shares position as of Q1 2016 after selling out during the quarter.
  • Arrowstreet Capital sold 10,600 NeuroDerm Ltd. Ordinary Shares shares in Q1 2016, an estimated $181K.
  • Arrowstreet Capital first reported a position in NeuroDerm Ltd. Ordinary Shares in Q4 2015 and held it in 1 quarter.
  • Arrowstreet Capital's NeuroDerm Ltd. Ordinary Shares position peaked at $181K in Q4 2015.
  • 50 funds tracked by Wall St. Rank held NeuroDerm Ltd. Ordinary Shares as of Q1 2016.

Based on Arrowstreet Capital's 13F filing for Q1 2016, filed 16 May 2016.